首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1345411

全球診斷電生理導管市場 - 2023-2030

Global Diagnostic Electrophysiology Catheters Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球診斷電生理導管市場在 2022 年達到 16 億美元，預計到 2030 年將達到 29 億美元，2023-2030 年預測期間年複合成長率為 8.1%。

診斷電生理學心臟病學領域的導管是專門的醫療設備，對於識別和了解各種心律失常和其他電生理異常至關重要。這些導管用於評估和診斷心臟異常電活動。它們通過血管引入心臟，並提供心臟電訊號的即時數據和映射。

診斷電生理學導管是針對特定應用而設計和配置的。它們有多個電極，能夠記錄來自心臟不同區域的電訊號。這有助於心臟病學家和電生理學家查明心律失常的根源並評估整體心臟功能。

此外，診斷電生理導管通常與先進的成像技術（例如透視和 3D 繪圖系統）結合使用，以增強可視化並提高導管放置的精度。此外，心律失常患病率的上升、電生理測繪系統的日益採用以及診斷電生理導管的創新預計將在預測期內推動市場發展。

動力學

主要市場參與者不斷推出的產品預計將推動市場成長

2022年10月13日，強生醫療科技子公司Biosense Webster發布HELIOSTAR球囊消融導管，是歐洲市場上第一款上市的射頻球囊消融導管。它專為與兼容的多通道射頻發生器一起使用時基於導管的心房心臟電生理測繪和心臟消融而設計。其獨特之處在於有十個鍍金沖洗電極，可以根據解剖位置和組織厚度進行客製化以提供功率。 HELIOSTAR 導管能夠進行圓周和分段消融，從而實現個性化肺靜脈 (PV) 消融。此外，獨立控制每個電極的功率輸送的能力增強了其靈活性和功效。

同樣，強生醫療科技旗下重要企業 Biosense Webster, Inc. 於 2023 年 7 月 24 日將採用 TRUEref 技術的 OPTRELL 標測導管引入美國心律失常治療市場。這種診斷導管與 CARTO 3 系統一起開發，具有固定陣列配置和高密度排列的小電極。這種配置非常適合複雜心律失常病例的精確電生理測繪，包括持續性心房顫動 (AFib)、重做 AFib 消融、房性心動過速和室性心動過速。

Biosense Webster 最近發布的 HELIOSTAR 和 OPTRELL 導管凸顯了創新技術在應對心臟電生理學挑戰方面的重要性。這些先進的工具滿足了對精確、高效和可客製化的心臟測繪和消融方法日益成長的需求。 Biosense Webster 致力於提高患者治療效果、簡化程序和改善心律失常治療的整體前景，這一點在這些新產品的發布中得到了體現。

診斷電生理學導管的創新預計將推動市場成長

2022 年 5 月 4 日，西門子 Healthineers 推出了 AcuNav Volume 4D ICE 導管，這是美國心內超聲心動圖 (ICE) 技術的重大進步。該導管的遠端尖端具有創新性，提高了關鍵結構的可操作性和可視化。這一發展使醫生能夠更接近解剖結構，並在結構性心臟手術期間提供更好的護理。

這項最新進展對於之前因經食管超聲 (TEE) 或全身麻醉等禁忌症而無法接受此類手術的患者以及三尖瓣反流患者尤其有益。該導管的設計還旨在提高醫院效率，減少導管實驗室周轉時間，並消除全身麻醉的需要。 AcuNav Volume ICE 導管在結構性心臟手術中的精確性和改善的結果進一步鞏固了西門子 Healthineers 作為診斷成像技術領導者的地位。

因此，由於 AcuNav Volume ICE 導管等先進導管的出現，診斷電生理導管市場可能會進一步成長，這將使患者、醫療保健提供者和整個行業受益。因此，由於上述因素，預計市場將在預測期內推動市場。

診斷電生理導管的高成本預計將阻礙市場成長

診斷電生理學導管及其所需設備的高額費用可能會阻礙其採用。其中一種導管是電生理導管 BIOSENSE WEBSTER：D7TCJ8L162RT，尺寸為 7 Fr，插入長度為 115 cm，J 曲線型，4 個電極，8 mm 尖端電極，間距為 1-6-2 mm，使其成為一種有前景的診斷干涉醫療工具。然而，儘管具有潛力，但在預計的預測期內，市場的成長可能會面臨重大障礙。每單位 600.97 美元的成本可能會對預算有限的醫療機構造成重大經濟障礙。

Overview

Global Diagnostic Electrophysiology Catheters Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.9 billion by 2030, growing with a CAGR of 8.1% during the forecast period 2023-2030.

Diagnostic Electrophysiology Catheters in the field of cardiology are specialized medical devices that are crucial in identifying and understanding various cardiac arrhythmias and other electrophysiological abnormalities. These catheters are used to assess and diagnose abnormal electrical activity in the heart. They are introduced into the heart through blood vessels and provide real-time data and mapping of the heart's electrical signals.

Diagnostic electrophysiology catheters are designed and configured for specific applications. They have multiple electrodes capable of recording electrical signals from different regions of the heart. This helps cardiologists and electrophysiologists to pinpoint the source of arrhythmias and evaluate the overall heart function.

Moreover, diagnostic electrophysiology catheters are often used in conjunction with advanced imaging technologies, such as fluoroscopy and 3D mapping systems, to enhance visualization and improve the precision of catheter placement. Furthermore, the rising prevalence of cardiac arrhythmias, increasing adoption of electrophysiology mapping systems, and innovations in diagnostic electrophysiology catheters are the factors expected to drive the market over the forecast period.

Dynamics

The Increasing Product Launches by the Key Market Players is Expected to Drive the Market Growth

On October 13, 2022, the HELIOSTAR Balloon Ablation Catheter was released by Biosense Webster, a subsidiary of Johnson & Johnson MedTech, and is the first radiofrequency balloon ablation catheter available in the European market. It is specifically designed for catheter-based cardiac electrophysiological mapping of the atria and cardiac ablation when used alongside a compatible multi-channel RF generator. Its unique feature is the presence of ten gold-plated, irrigated electrodes, which can be customized to deliver power based on anatomical location and tissue thickness. The HELIOSTAR catheter is capable of both circumferential and segmental ablation, which allows for personalized pulmonary vein (PV) ablation. Additionally, the ability to control power delivery to each electrode independently enhances its flexibility and efficacy.

Similarly, on July 24, 2023, the OPTRELL Mapping Catheter with TRUEref Technology was introduced to the cardiac arrhythmia treatment market in the U.S. by Biosense Webster, Inc., a significant player under Johnson & Johnson MedTech. This diagnostic catheter, developed alongside the CARTO 3 System, features a fixed array configuration with a high-density arrangement of small electrodes. This configuration is ideal for precise electrophysiological mapping in complex cardiac arrhythmia cases, including persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.

The recent release of the HELIOSTAR and OPTRELL catheters by Biosense Webster highlights the importance of innovative technologies in addressing challenges in cardiac electrophysiology. These advanced tools cater to the increasing need for precise, efficient, and customizable approaches to cardiac mapping and ablation. Biosense Webster's dedication to enhancing patient outcomes, simplifying procedures, and improving the overall landscape of arrhythmia treatment is evident in these new product launches.

Innovations in Diagnostic Electrophysiology Catheters are Expected to Drive Market Growth

On May 4, 2022, Siemens Healthineers introduced the AcuNav Volume 4D ICE Catheter, which is a significant advancement in intracardiac echocardiography (ICE) technology in the United States. The catheter's distal tip is innovative, improving maneuverability and visualization of critical structures. This development enables physicians to get closer to the anatomy and provide better care during structural heart procedures.

The latest advancement is especially beneficial for patients who were previously unable to undergo such procedures due to contraindications like transesophageal echo (TEE) or general anesthesia, as well as those with tricuspid regurgitation. The catheter's design also aims to enhance hospital efficiency, reduce cath lab turnaround time, and eliminate the need for general anesthesia. Siemens Healthineers' position as a leader in diagnostic imaging technology is further strengthened by the AcuNav Volume ICE Catheter's precision and improved outcomes in structural heart procedures.

Therefore, the diagnostic electrophysiology catheters market could experience further growth due to the availability of advanced catheters like the AcuNav Volume ICE Catheter, which would benefit patients, healthcare providers, and the industry as a whole. Hence, owing to the above factors, the market is expected to drive the market over the forecast period.

High Cost for Diagnostic Electrophysiology Catheters Adoption is Expected to Hamper the Market Growth

The high expenses associated with diagnostic electrophysiology catheters and their required equipment can hinder their adoption. One such catheter, the Electrophysiology Catheter BIOSENSE WEBSTER: D7TCJ8L162RT, has a size of 7 Fr, an insertion length of 115 cm, a J-curve type, 4 electrodes, an 8 mm tip electrode, and a spacing of 1-6-2 mm, making it a promising medical tool for diagnostic interventions. However, despite its potential, the market's growth may face significant obstacles during the projected forecast period. The cost of $600.97 per unit may create a significant economic barrier for healthcare facilities with limited budgets.

Segment Analysis

The global diagnostic electrophysiology catheter market is segmented based on type, technology, end user and region.

The RF Ablation Catheters from the Type Segment Accounted for Approximately 38.9% of the Diagnostic Electrophysiology Catheters Market Share

Radiofrequency (RF) Ablation Catheters are advanced medical devices used in different procedures to treat conditions such as cardiac arrhythmias and specific tumors. These catheters use controlled radiofrequency energy to destroy abnormal tissue without requiring open surgery. They offer advantages such as enhanced accuracy in targeting specific tissue, decreased patient discomfort, shorter recovery periods, and reduced risks compared to traditional surgical methods.

For instance, Medtronic, The 7 French RF Marinr Multi-Curve Steerable Catheter is a specialized medical tool used in minimally invasive interventional cardiology procedures. It has a diameter of 7 French and is designed to navigate the cardiovascular system with ease, thanks to its multiple pre-shaped curves that enhance maneuverability.

This catheter is primarily intended for radiofrequency ablation, which is used to treat cardiac arrhythmias by delivering controlled energy to selectively destroy irregular heart tissue. The catheter's steerable capabilities enable precise navigation through complex pathways, which improves control for accessing challenging anatomical sites and performing delicate procedures effectively.

When combined with RF ablation, this catheter enhances patient outcomes, reduces procedure times, and increases comfort compared to traditional surgical methods. To ensure optimal use and patient care, healthcare professionals must receive proper training in using this catheter.

Furthermore, the RF Ablation catheter market is driven by factors such as the increasing prevalence of cardiac arrhythmias, rising demand for minimally invasive treatment options, and advancements in catheter technology.

For instance, on March 15, 2023, received CE (Conformite Europeenne) Mark for the Affera Mapping and Ablation System, which includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software.

Moreover, Atrial fibrillation (AFib) is the most common atrial arrhythmia, and nearly 60 million people are affected worldwide and five million patients will be added every year by 2030. Atrial arrhythmias, such as AFib, are associated with serious complications including heart failure, stroke, and increased risk of death.

Additionally, on May 15, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that data from the Q-FFICIENCY study was published in JACC: Clinical Electrophysiology. The study evaluated the safety and 12-month effectiveness of the QDOT MICRO Catheter in paroxysmal atrial fibrillation (AFib) ablation using the very high-power short-duration (QMODE+) mode combined with conventional-power temperature-controlled (QMODE) mode.

The Biosense Webster QDOT MICRO Catheter is a next-generation RF ablation catheter that was granted CE Mark in 2020 and FDA approval in 2022. This catheter is designed to provide improved procedural efficiency and ablation efficiency for treating atrial fibrillation (AF). It is the world's first very high-power, short-duration ablation catheter.

Nevertheless, the market growth can be impeded by challenges like limited awareness among patients and healthcare professionals, high upfront costs of equipment, and the requirement for specialized training to operate the devices effectively. Therefore, these obstacles require continuous medical education, cost-effective solutions, and ongoing research to demonstrate the safety and efficacy of RF ablation procedures.

Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing FDA Approvals, Growing Product Launches, and Presence of Key Market Players in the Region

North America region is expected to hold the largest market share over the forecast period owing to the increasing FDA approvals, growing product launches, and presence of key market players in the region. For instance, on February 2, 2023, Abbott announced two approvals as part of its growing suite of electrophysiology products in the global market. The company's TactiFlex Ablation Catheter, Sensor Enabled, the world's only ablation catheter with a flexible tip and contact force sensing, received CE Mark for treating people with abnormal heart rhythms like atrial fibrillation (AFib). Abbott's FlexAbility Ablation Catheter, Sensor Enabled also recently secured an expanded indication for treating patients with a complex heart condition by the U.S. Food and Drug Administration (FDA).

Similarly, on February 2, 2023, MicroPort EP obtained approval from the Food and Drug Administration in the United States of America (U.S.) for its independently researched and developed EasyFinder Fixed Curve Diagnostic Catheter. This product is the first mapping catheter from MicroPort EP to get FDA approval.

Therefore, the approval of more diagnostic electrophysiology catheters by the FDA in the region has a significant positive impact on the market. It encourages innovation, improves patient care, increases clinical confidence, attracts investments, and establishes the region as a leader in the field. Moreover, there is potential to revolutionize the diagnosis and treatment of heart rhythm disorders, leading to benefits for both healthcare providers and patients. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the diagnostic electrophysiology catheters market include: Abbott Laboratories, Boston Scientific Corporation, Johnson and Johnson (Biosense Webster), Integer Holdings Corporation, Medtronic, Lepu Medical Technology (Beijing)Co., Ltd., Access Point Technologies EP., BIOTRONIK, CathRx Ltd. and Siemens Healthineers among others.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the diagnostic electrophysiology catheters market. Due to the pandemic's peak, hospitals had to delay or cancel elective procedures, including diagnostic electrophysiology procedures. As a result, the usage of diagnostic electrophysiology catheters decreased, and healthcare resources were redirected toward managing COVID-19 cases.

Patients with non-urgent cardiac conditions often postpone routine check-ups and diagnostic tests due to their fear of exposure to the virus. This decrease in patient visits resulted in less demand for diagnostic electrophysiology catheters. The focus of hospitals and medical facilities shifted to managing COVID-19 cases, which meant that essential and life-threatening procedures took priority. Elective diagnostic procedures like electrophysiology studies using catheters were deprioritized during this time. The pandemic also had an impact on research and development activities, with potential delays to the introduction of new and innovative diagnostic electrophysiology catheter technologies to the market.

With the improving situation of the pandemic and the stabilization of healthcare systems, the market for Diagnostic Electrophysiology Catheters is anticipated to slowly bounce back. The demand for precise diagnosis and treatment of heart conditions is still present, and the market is expected to recover as elective surgeries resume, patients regain trust, and healthcare resources are redirected toward non-COVID-19-related services.

By Type

RF Ablation Catheters
Alternative Energy Ablation Catheters
- Cryoablation
- Laser Ablation
- Ultrasound

High-Density Mapping Catheters
ICE Catheters

By Technology

Fixed Curve Diagnostics Catheters
Steerable Diagnostics Catheters

By End User

Hospitals
Ambulatory Surgical Centers
Cardiac Catheterization Laboratories
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

On July 24, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced the U.S. launch of the OPTRELL Mapping Catheter with TRUEref Technology powered by the CARTO 3 System. The OPTRELL Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
On September 06, 2022, Royal Philips, a global leader in health technology, announced that Baptist Health's Miami Cardiac & Vascular Institute (Florida, U.S.) successfully started treating patients with Verisight Pro, Philips' real-time 3D Intracardiac Echocardiography (ICE) catheter, during minimally-invasive image-guided procedures for structural heart disease. Offering superior 2D and 3D live imaging, VeriSight Pro allows interventionalists to navigate procedures with ease, provide superior care, and optimize the performance of the interventional suite to benefit more heart patients.

DataM Intelligence Opinion:

According to DataM Intelligence, the diagnostic electrophysiology catheter market is being driven by new and innovative products, such as the HELIOSTAR Balloon Ablation Catheter and AcuNav Volume 4D ICE Catheter. These advancements demonstrate the industry's dedication to improving cardiac electrophysiology tools.

However, the COVID-19 pandemic has created challenges for the market, including delays in procedures and fewer patient visits. Despite these setbacks, the market is expected to recover due to the importance of accurate diagnosis, ongoing advancements, and North America's strong presence in the industry, thanks to FDA approvals. Collaboration between medical professionals, researchers, and manufacturers will be crucial in shaping the future of the market, improving patient care, and making the industry more adaptable. This will lead to sustained growth and a positive global impact.

Why Purchase the Report?

To visualize the global diagnostic electrophysiology catheters market segmentation based on type, technology, end user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of diagnostic electrophysiology catheters market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global diagnostic electrophysiology catheters market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Technology
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The Increasing Product Launches by the Key Market Players
  - 4.1.1.2. Innovations in Diagnostic Electrophysiology Catheters
- 4.1.2. Restraints
  - 4.1.2.1. High Cost for Diagnostic Electrophysiology Catheters Adoption
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Patent Analysis
5.7. Russian-Ukraine Conflict Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. RF Ablation Catheters*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Alternative Energy Ablation Catheters
- 7.3.1. Cryoablation
- 7.3.2. Laser Ablation
- 7.3.3. Ultrasound
7.4. High-Density Mapping Catheters
7.5. ICE Catheters

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Fixed Curve Diagnostics Catheters*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Steerable Diagnostics Catheters

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Cardiac Catheterization Laboratories
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Abbott Laboratories*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Boston Scientific Corporation
12.3. Johnson and Johnson (Biosense Webster)
12.4. Integer Holdings Corporation
12.5. Medtronic
12.6. Lepu Medical Technology (Beijing)Co.,Ltd.
12.7. Access Point Technologies EP
12.8. BIOTRONIK
12.9. CathRx Ltd.
12.10. Siemens Healthineers

LIST NOT EXHAUSTIVE